Stephen J. Carriere - 19 Jan 2022 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
Principal Accounting Officer
Signature
/s/ Daniel S. Char, Attorney-in-Fact for Stephen J. Carriere
Issuer symbol
EVLO on OTC
Transactions as of
19 Jan 2022
Net transactions value
$0
Form type
4
Filing time
21 Jan 2022, 16:02:48 UTC
Previous filing
29 Sep 2021
Next filing
23 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +6,250 $0.000000 6,250 19 Jan 2022 Common Stock 6,250 $5.05 Direct F1
transaction EVLO Restricted Stock Units Award $0 +1,417 $0.000000 1,417 19 Jan 2022 Common Stock 1,417 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates.
F2 These RSUs will vest in four substantially equal annual installments at the end of each annual anniversary of the date of grant, subject to continued employment on such dates.